CMAJ • May 11, 2004; 170 (10). doi:10.1503/cmaj.1011625.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Léger, C. S.
Right arrow Articles by Nevill, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Léger, C. S.
Right arrow Articles by Nevill, T. J.
Related Collections
Right arrow Hematologic pathology (including blood transfusion)

Review
Synthèse

Hematopoietic stem cell transplantation: a primer for the primary care physician

Chantal S. Léger and Thomas J. Nevill

From the Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, St. Paul's Hospital (Léger), Vancouver General Hospital (Nevill), the British Columbia Cancer Agency (Nevill) and the University of British Columbia (Léger, Nevill), Vancouver, BC

Abstract

HEMATOPOIETIC STEM CELL TRANSPLANTATION has been used for many years to treat various malignant and nonmalignant hematologic conditions. However, the high-dose conditioning regimen can lead to major organ dysfunction, life-threatening infection and bleeding. In the allogeneic setting, graft-versus-host disease may also develop, making post-transplant management complex. Once a transplant recipient is discharged from hospital and returns to his or her local community, the primary care physician can play an important role in care. Recipients of stem cell transplants may be severely immunocompromised for many months after transplantation, especially if they are still taking immunosuppressive drugs. Furthermore, endocrine and metabolic deficiencies can develop, and transplant survivors are at risk of a second malignant disease. This review is intended as a basic overview of allogeneic and autologous stem cell transplantation with a special focus on long-term follow-up issues relevant to primary care providers.




This article has been cited by other articles:


Home page
 JCOHome page
J. M. Prieto, J. Atala, J. Blanch, E. Carreras, M. Rovira, E. Cirera, A. Espinal, and C. Gasto
Role of Depression As a Predictor of Mortality Among Cancer Patients After Stem-Cell Transplantation
J. Clin. Oncol., September 1, 2005; 23(25): 6063 - 6071.
[Abstract] [Full Text] [PDF]